Green strategy for gaining competitive advantage in pharmacy: Exploring the role of green and social innovation by Budi Nur Siswanto, Irayanti Adriant, Rizqi Permana Sari, Agus Rahayu

“…This study aims to explore the influence of green strategy on social innovation and green innovation and its impact on competitive advantage in pharmaceutical companies. A sample of 53 respondents consisting of the private sector and state-owned enterprises was selected in this study and then analyzed using a structural equation model (SEM-PLS). …”
Get full text

Impacts of National Reimbursement Drug Price Negotiation on drug accessibility, utilization, and cost in China: a systematic review by Zheng Zhu, Jiawei Zhang, Zhihu Xu, Quan Wang, Yu Qi, Li Yang

“…Abstract Objective National Reimbursement Drug Price Negotiation (NRDPN) refers to a government-led process of negotiating with pharmaceutical companies to reach reasonable prices for exclusive drugs covered by national reimbursement. …”
Get full text

Sécurité sanitaire sous dépendance by Marie Coris, Alain Piveteau, Philippe Gorry, Matthieu Montalban

“…But the debate has failed to understand the complexity of the determining factors in the location of pharmaceutical companies and to overcome the contradictions at work in this productive and security crisis. …”
Get full text

Undigested Pills in Stool Mimicking Parasitic Infection by Fazia Mir, Ilyas Achakzai, Jamal A. Ibdah, Veysel Tahan

“…Controlled release preparations were developed by pharmaceutical companies to improve compliance and decrease frequency of pill ingestion. …”
Get full text

COVID-19 vaccination: challenges in the pediatric population by Alice Nicoleta Azoicai, Ingrith Miron, Ancuta Lupu, Monica Mihaela Alexoae, Iuliana Magdalena Starcea, Mirabela Alecsa, Vasile Valeriu Lupu, Ciprian Danielescu, Alin Horatiu Nedelcu, Delia Lidia Salaru, Felicia Dragan, Ileana Ioniuc

“…In response, several pharmaceutical companies rapidly leveraged their resources to develop vaccines within a very short period of time, leading to the introduction of new, improved, and combination vaccines for community-wide immunization. …”
Get full text

Façonner la prescription, influencer les médecins by Jérôme Greffion, Thomas Breda

“…They represent at least 20 % of the turnover of this sector and drug detailing request up to 40 % of the total staff of the large pharmaceutical companies, which have become marketing giants. …”
Get full text

Signaling Pathway Puts the Break on Fat Cell Formation by Ormond A. MacDougald

“…These environmental factors may be complicated in some individuals by an unfavorable genetic predisposition. Pharmaceutical companies lead active research programs to identify drugs that target weight control centers in the body and which may help individuals control their weight; however, no satisfactory magic bullet to fight obesity has yet come through the pipeline [7,8].…”
Get full text

The potential of three-dimensional printing for pediatric oral solid dosage forms by Kreft Klemen, Fanous Marina, Möckel Volker

“…In this setup, pharmaceutical companies would routinely provide materials and instructions for 3D printing, while specialized compounding centers or hospital pharmacies perform the printing of medication. …”
Get full text

Dangerous Liaisons? by Norman L Jones

“…A case in point was a few days last month during which I attended a well-sponsored meeting of the Ontario Lung Association, reviewed a couple of papers reporting drug trials, read of the threats of litigation made by pharmaceutical companies to two Ontario researchers, heard of a public apology made by the New England Journal of Medicine regarding reviewers' conflicts of interest and received a critical letter from Dr Rob McFadden, an associate editor of the Canadian Respiratory Journal, about a sponsored publication that accompanied the last issue of 1999. …”
Get full text

Advancing the development of real-world data for healthcare research in China: challenges and opportunities by Jun Zhang, Eric Wu, Jia Zhong, Honghao Fang, Larry Liu, Jipan Xie

“…A workshop with 30 representatives from healthcare research agencies, technology companies focused on healthcare big data and pharmaceutical companies was held in December 2020 to identify strategies to overcome the barriers associated with the usability and quality of RWD in China. …”
Get full text

Accessibility of COVID-19 Vaccines in African Countries: A System Dynamics Model Examining Income, Logistics, and Governance by Oya Öztürk, Muhammed Çelik

“…To combat the COVID-19 pandemic, pharmaceutical companies, biotech companies, national governments, and universities have jointly developed a variety of vaccines. …”
Get full text

Prevalence of Pharmaceuticals in Surface Water Samples in Ghana by David Azanu, David Adu-Poku, Selina Ama Saah, William Ofori Appaw

“…The estimated risk quotient values for antibiotics resistance were above 1 for all the antibiotics investigated in surface water impacted by the wastewater of hospitals and pharmaceutical companies’ except surface water impacted by sewage treatment plants (STPs) and market wastewater. …”
Get full text

Evolutionary game and simulation analysis of tripartite subjects in public health emergencies under government reward and punishment mechanisms by Dandan Gao, Wei Guo

“…The research findings indicate that (1) For the tripartite entities of public health emergencies, the key for strategy choices is to reduce the gain obtained from illegal production and non-cooperation with prevention and control. (2) The strength of the initial willingness to participate has a significant effect on the evolution strategies of each subject. (3) For pharmaceutical companies and the public, the incentives and penalties of local governments can promote the former’s compliance and the latter’s cooperation in prevention and control. …”
Get full text

Risk Assessment for Complex Systems Based on Fuzzy Cognitive Maps: A Case of the Biopharmaceutical Industry by Hadi Abbasian, Reza Yousefi-Zenouz, Abdollah Amirkhani, Masoud Shirzadeh, Akbar Abdollahiasl, Shekoufeh Nikfar, Mohammadreza Siahi-Shadabad, Abbas Kebriaeezadeh

“…The proposed FCM features and the knowledge gained from evaluating them can provide practical and helpful information to pharmaceutical companies to deal with their supply risks more efficiently.…”
Get full text

Canadian Standards Association Standard CAN/CSA/Z264.1-02:2002: A New Voluntary Standard for Spacers and Holding Chambers Used with Pressurized Metered-Dose Inhalers by Myrna B Dolovich, Jolyon P Mitchell

“…This consensus standard was developed with the support of pharmaceutical companies and manufacturers of spacers and holding chambers, and with the help of clinicians, retail pharmacists and representatives of patient advocate bodies associated with respiratory diseases and the dissemination of information related to the treatment and the delivery of inhaled medications. …”
Get full text

Pervasive systemic disparities: medical-related gaslighting, trauma, and distrust among LGBTQ+ people in the United States by Dustin Z. Nowaskie, Dehandra Blackwood, Frank Garcia

“…Likewise, LGBTQ+ people conveyed significantly less trust (ORs 0.46–0.53) in primary care providers (59.8% vs. 74.1%), medical specialists (56.5% vs. 71.7%), pharmaceutical companies (17% vs. 28%), insurance companies (15.9% vs. 29.3%), and U.S. healthcare systems (17.8% vs. 30.4%).DiscussionMedical-related gaslighting, trauma, and distrust are pervasive systemic disparities among LGBTQ+ people. …”
Get full text

COVID-19 CONSPIRACISM IN THE AGE OF POST-TRUTH by Ömer Ersin Kahraman

“…Consequently, this period has also witnessed the diffusion of conspiracy theories varying from accusations which consider the rapid propagation of the virus as a plot of states and big pharmaceutical companies to allegations which presume the pandemic as a hoax to implement new communication technologies like 5G. …”
Get full text

Transformations of Medical and Vaccine Diplomacies in the COVID-19 Era by I. I. Arsentyeva

“…The article examines the current policy of China, as it has achieved the most notable success in medical services export, primarily to developing countries, and Chinese pharmaceutical companies play a prominent role in the global vaccine market. …”
Get full text

Suitability of paediatric legislation beyond the USA and Europe: a qualitative study on access to paediatric medicines by Albrecht Jahn, Rosa Jahn, Anna Volodina

“…This study explored whether similar policies could improve access to medicines in other countries.Methods We conducted 46 interviews with representatives from healthcare practice, patient organisations and health authorities from six countries (Australia, Brazil, Canada, Kenya, Russia and South Africa) as well as multinational pharmaceutical companies exploring their views regarding access barriers to paediatric medicines. …”
Get full text

Impact of the Clinical Trials Act 2018 on clinical trial activity in Japan from 2018 to 2020: a retrospective database study using new and conventional Japanese registries by Hiroyuki Taruno, Mari S Oba, Osamu Takizawa, Kayoko Kikuchi, Kazuaki Matsui, Mayumi Shikano

“…The temporal trends in clinical trial activity after CTA enactment were examined.Results A total of 577 CTA-compliant specified clinical trials (ie, studies funded by pharmaceutical companies or studies evaluating the efficacy and safety of off-label drugs or devices in humans) were registered in the jRCT. …”
Get full text